The transition occurred in nearly 75% of this study population, and researchers found that a prescription for a non-fluticasone-salmeterol dry-powder inhaler in this group was reported in 14.2% of ...

Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...

The Annals of Pharmacotherapy. 2009;43(3):519-527.

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...